Answers are grounded in this paper and cite their sources.
Nanoparticle-based drug delivery is an emerging strategy in drug research due to its ability to protect the drug from degradation, control the release of a drug and deliver the drug to specific tissues. Creating appropriate formulations of nanoparticles, however, is time consuming because many factors play a role in the physical properties and the performance of nanoparticles in the body. Artificial intelligence (AI), such as machine learning (ML) and deep learning (DL), could aid with this process by sifting through experimental data and uncovering patterns that might be beneficial. The review focuses on recent advances in the design, selection of materials, formulation development and optimization using AI in the design of nanoparticles. It also explains the basics of drug loading, encapsulation efficiency, drug-release profile, particle size, polydispersity index (PDI), and zeta potential that can be estimated using AI-based models.They are also beginning to be discussed in the context of targeted delivery, such as identification of targets, surface engineering and prediction of interactions between nanoparticles and biology. In addition, examples of application in cancer therapy, RNA loaded lipid nanoparticles, drug delivery to the cardiovascular system and arthritis therapy and personalized nanomedicine are emphasized. Recent progress in the field of nanoinformatics, big data analysis, quality by design (QbD) approaches with the aid of artificial intelligence, and multiscale modelling further opens the potential for more systematic development of nanocarriers. While achieving these breakthroughs, data quality, a lack of datasets, model interpretability, experimental validation, and standardization and regulatory requirements are still significant hurdles to clinical translation. In summary, the combination of AI and the use of nanoparticles could play a role in enhancing the drug delivery development process by providing more efficient, predictive, and personalized strategies, provided that computational predictions are complemented with experimental validation and reliable data.[1]
No takes yet. Share an insight, caveat, or question.
Lanke et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: